Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are over 18 years old
- You have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a tissue or cell sample test
- Your cancer is at an advanced or spread stage (stage IIIB-IV) that cannot be removed by surgery, or it has come back or spread after surgery
- You have at least one tumor that can be measured and tracked using standard medical imaging
- Your cancer has tested positive for a specific gene change called an EGFR mutation, confirmed by a tissue or fluid sample
- You have been treated with a specific approved type of targeted drug (a third-generation EGFR-TKI) as your first treatment for this cancer
- You are willing to share your medical records, scan results, and samples for research purposes, and agree that your data may be used for future research and product development
- You are willing to take part in the study and sign a consent form
Who may not be able to join:
- People who are unable to understand what the study involves or are unwilling to sign the consent form
- Women who are currently pregnant or breastfeeding
- People who have had another type of cancer within the last 3 years
- People who are currently taking part in, or have taken part in, another clinical drug trial
- People who have received any full-body (systemic) cancer treatment within the last 2 years
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate (ORR); Progression-free survival (PFS); Differences in genomic profiles of tumor tissues and ctDNA clearance of third-generation EGFR-TKIs sensitive and primary drug-resistant NSCLC.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.